»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ VkRvmKYl
z X2BJ
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 Me`jh8(K\6
Z>wg
o@z%
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© A+iQH1C0h
1.Antigen presenting cell£¨APC£© u/hFf3
2.Activation induced cell death£¨AICD£© #hH "g
3.Chemokine y9=/kFPRm
4.Major histocompatibility complex£¨MHC£© |F iL1_
5.immunotolerance gX{V>T(<
15)=>=1mR.
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© dScit!T"
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ CGbW]D$@
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà xzyV|(
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ i
jg'X#E
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ F7E# x
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã :y"Zc1_
E
erdWGUfQOe
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© >Yl?i&3n
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ )U6T]1
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ }mxy6m ,
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ pfe9n[
p,* rVz[Y
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ?}D@{%O3T
aW$sd)
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 Sy6Y3 ~7
%?' jyK
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ c*'D
1.Antigenic determinant nr
Jl>H
2.IgSF ;dPyhR
3.MBL;¾¶ jqPQ=X
4.chemokine vj]-p=
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ VC:.ya|Z
6.TCR-CD3¸´ºÏÎï Du k v[/60
7.FADD£¨Fas-associated protein with death domain£© x=pq-&9>B
8.AIDS c:.k2u
9.Tumor rejection antigen 5`53lK.C
10.AICD bF;g.-.2
3R1v0
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ tY-{uHW&h
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© IGeXj%e
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ nsQx\Tnhx
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ ak 94"<p
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì ^a#Vp
PJA%aRP,:
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ `bw>.Ay
(%=[J/F/
~1jSz-s
רҵ¿Î ÃâÒßѧ
3=@94i
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê f'` QW@U
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell
pbM~T(Y8
5. Fc¦Å receptor 6. Cytokine Ea#wtow|-
¶þ¡¢ ÎÊ´ðÌâ ^iAOz-H
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 6}zargu(;
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ 'o;>6u<u
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ eT* )r~
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 [+<lm
5t
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠOPHf9T3H
<2@V$$Qg.~
;K]6/Wt
}{/3yXk[G
C\#E1\d
f'._{"
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ WfYu-TK*
-wJ/j~+m+
qXC>DGy
רҵ¿Î ÃâÒßѧ =w&JDj
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê =s3f{0G
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen do0;"O0
(
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin
2w6y
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test >~C*m `#
9. Hybridoma technic 10.Mitogen \0.
c_
11.Dentritic cell 12.Immunoproliferation X633.]+
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ "\0&1C(G
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ a?&{eMEe}
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ.
KH3.v/c|
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ rfj>/?8!@
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ gG5@ KD6k
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ Tp7*T8
Z:51Q
:f1Q0klwP
7ip$#pzo
L#)F00/`
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 9em?2'ysa
yffg_^fR
x""gZzJ$L
רҵ¿Î ÃâÒßѧ ``
!BE"yN
Ò»¡¢ Ãû´Ê½âÊÍ dw6U}
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï b=Rw=K.
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà *>b*I4dz
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ iIZDtZFF
¶þ¡¢ ÎÊ´ðÌâ qHM,#W<
1¡¢ TÁÜ°Íϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ Na6z1&wS
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁÜ°Íϸ°ûºÍЧӦÎïÖÊ¡£ W ='c+3O6
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆ乲ͬÌص㼰ÓëÁÙ´²µÄ¹Øϵ¡£ ,_ zivUU
4¡¢ ºÎνÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ 4.>rd6BAN-
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØϵͳ£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ a!OS2Tz:
heLWVI[so
sR(or=ub~
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 8oAr<:.=
2.xA' \M
dCbRlW
רҵ¿Î ÃâÒßѧ ^T^l3B[
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê V5]}b[X
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR BYhF?
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA wNNInS6
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM %s|`1`c
¶þ¡¢ ÎÊ´ðÌâ @/(\YzQvp]
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌص㡣 2N)siH
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ 1R}rL#h;=
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖƵÄÒìͬµã¡£
>M2~BDZ
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆ书ÄÜ¡£ T/m4jf2
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ mNc?`G_R
XB
vJc'(s
%S'gDCwq
\3WF-!xe
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ <./r%3$;7
V8C62X
a/@F?\A
רҵ¿Î ÃâÒßѧ _S$SL%;\
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê FV 0x/)<z
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule yF [|dB
5. Autogous mixed lymphoyte reaction x>C_O\
¶þ¡¢ ÎÊ´ðÌâ Zk={3Y
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ \H^A@f
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ k=^~\$e
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠP(Gv|Q@
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹Øϵ£¿ \dx$G?R
g"KH~bN
oe4r_EkYwW
X2[d15!9
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ :j<ij]rsI
;ndwVZ~,
='[J.
רҵ¿Î ÃâÒßѧ Gg,&~
jHib
!GAU?J;<#2
`[(.Q
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê H\PY\O&cP
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance F7"v}K]X
5. Delayed type hypersensitivity #
o;\5MOE%
¶þ¡¢ ÎÊ´ðÌâ #}lq2!f6
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ &tjv.t
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ ir?Y
>
3. ¼òÊöHLAÓëҽѧµÄ¹Øϵ¡£ \'>8 (i~
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ( +x!wX( x
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óá£
!A|ayYBb\
HX`>"
?{
gP^p7aYwn
%"gV
>E_u
r;"uk+{i
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ JA]qAr
k3-7Vyg
kKHGcm^r
רҵ¿Î ÃâÒßѧ bpaS(nBy
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê *S?vw'n
1. hypersensitivity 2. cluster of differentiation m`lxQik
3. adhesion molecules 4. supper antigen 5. split tolerance Cu,#w3JR
¶þ¡¢ ÎÊ´ðÌâ :&-j{8p-
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ g+zfa.wQ
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ =JM !`[
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ (q+EP(Q
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ G@+AB*Eu
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ O@)D%*;v
sR*.i?lN
q*pWx]Y
1cvH
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 9i`sSi8
רҵ¿Î ÃâÒßѧ QBwgI>zfS"
Ò»¡¢ Ãû´Ê½âÊÍ 9?i~4&EY
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å ,EuJ0
]2
5. GVHR #CcWsI>+w>
¶þ¡¢ ÎÊ´ðÌâ xZ.c@u6:
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠ"U6
:z M
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌصãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ qFwJ%(IQ
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌص㡣 cpe/GvD5]
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ u''~nSR3&
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ 50VH>b_
tiHP?N U
Lr ;PESV
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ GT(nW|v
gZ&' J\
0{'%j~"
רҵ¿Î ÃâÒßѧ _WeN\F~^
Ò»¡¢Ãû´Ê½âÊÍ d%C:%d
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å ZA!yw7~
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ @ApX43U(
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ -0R;C` (!
11. »ìºÏÁÜ°Íϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ {24Y1ohK
Èý¡¢ ÎÊ´ðÌâ hJIF!eoI
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ YnLwBJ 2i
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ V {H/>>k7
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà (}:n#|,{M
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ $,v[<T`
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ fj,]dQT
sKU?"|G81G
x-3!sf@
u>U4w68
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 3$hbb6N%6.
V`;$Ua;y
hExw} c
רҵ¿Î ÃâÒßѧ )rP)-op|A
Ò»¡¢Ãû´Ê½âÊÍ yk<$XNc
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó G>q16nS~KP
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁÜ°Íϸ°ûµÄ±íÃæ±êÖ¾ pPX ~pPIj2
Èý¡¢ ÎÊ´ðÌâ $4j$c|S!
1. ¼òÊöTÁÜ°Íϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ nR()ei^X
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ 8iDg2_l`G
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ BL&
D|e
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ ZX
Sl+k.
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ 4\6-sL?rW
*xl930y
az=(
6PX
e~wJO~
k'd(H5A
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ jD
eNCJ
Ò»¡¢Ãû´Ê½âÊÍ [v!TQwMU
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï C;3>q*Am4
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó S24wv2Uw i
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ Q6|~ks+Y
¶þ¡¢ ÎÊ´ðÌâ =c>w
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ d5x>kO'[l
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ qPc"A!-i
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ 3/w) mY-o
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ Mw
lhL?
s]X]jfA.
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ mu(EmAoenQ
Ò»¡¢ Ãû´Ê½âÊÍ i'Oh^Y)E#
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ c
QjzI#
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ AV0C9a/td
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© B>11
10¡¢ ÒõÐÔÑ¡Ôñ Ikkv <uY
¶þ¡¢ ÎÊ´ðÌâ _l`s
}yC
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 3KF[ v{
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ l1RpG"
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 mkCv
f
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ 88dq8T4
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. {&'u1y R
1!x-_h}
2EeWcTBU}.
axl!zu*
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 8q6b3q:c
HqW|
JZ[~3swR
רҵ¿Î ÃâÒßѧ uLw$`ihw
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ KfXE=v{t
1. Cytokines 2. adhesion molecules 3. graft versus host reaction U20G{%%
4. immunologic tolerance 5. Opsonization ])=k";76
Èý¡¢ ÎÊ´ðÌâ .TN9N
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠndkV(#wQS
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ NXvu}&H
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ '"
H'#%RU
4. ÃâÒßϵͳɱÉË°Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ qY24Y
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ {*8'bNJ
H)$-T1Wx4
,zy4+GW
;as4EqiK
Kq|L:Z
54kd>)|"ag
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ u-zl- ?Ne
#c5 NFU}9
E3#}:6m
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ ~n#rATbxf
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ Mg.xGST
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê J9^RP~>bs
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ -Cxk#-sb#
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û '&5A*X]d
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö 1(`>9t02/?
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð 4/$ $?w4
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖƱ¸ÔÀí¡£ C+-xC~
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ ^'=J'Q
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃ濹ԺͱíÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© DCv~^
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ Pew-6u"
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ }"j7Qy)cs
Vkdchc
-Cwx %
r5z_{g
MoN;t;
h>w4{ u0
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ +1Oi-$
2-
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ m]JZ@
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ [^B04x@
/"+n{*9
Ò»¡¢ Ãû´Ê½âÊÍ \w{x-}
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß s`ly#+!.
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò FA?xp1E
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô ]?tsYXU j
¶þ¡¢ÎÊ´ðÌâ |l(rR06#.]
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ QD%~A0
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì %zQME6WELz
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì F MB\$(g
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ Er?Wg 09
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ P]-d(N}/H
Ub%+8M